Etalocib
Etalocib is a chemical compound that has been studied for its potential use in the treatment of various cancers and inflammatory diseases. It is classified as a selective inhibitor of the 5-lipoxygenase (5-LO) enzyme and the peroxisome proliferator-activated receptor gamma (PPAR-γ).
Mechanism of Action[edit | edit source]
Etalocib works by inhibiting the activity of the 5-lipoxygenase enzyme, which is involved in the production of leukotrienes. Leukotrienes are inflammatory mediators that play a significant role in the pathogenesis of asthma, allergic rhinitis, and other inflammatory conditions. By inhibiting 5-LO, Etalocib reduces the production of leukotrienes, thereby decreasing inflammation.
Additionally, Etalocib acts as an agonist of PPAR-γ, a nuclear receptor that regulates the expression of genes involved in glucose and lipid metabolism, as well as inflammation. Activation of PPAR-γ has been shown to induce apoptosis (programmed cell death) in certain cancer cells, making Etalocib a potential therapeutic agent in oncology.
Clinical Studies[edit | edit source]
Etalocib has been evaluated in several clinical trials for its efficacy and safety in treating various types of cancer, including non-small cell lung cancer (NSCLC) and pancreatic cancer. Preliminary results have shown that Etalocib may have anti-tumor activity, particularly when used in combination with other chemotherapeutic agents.
Potential Applications[edit | edit source]
Cancer[edit | edit source]
Etalocib has shown promise in the treatment of several types of cancer, including:
Inflammatory Diseases[edit | edit source]
Due to its anti-inflammatory properties, Etalocib is also being investigated for the treatment of inflammatory diseases such as:
Side Effects[edit | edit source]
The side effects of Etalocib are still being studied, but some reported adverse effects include:
Conclusion[edit | edit source]
Etalocib is a promising compound with potential applications in both oncology and inflammatory diseases. Ongoing research and clinical trials will further elucidate its efficacy and safety profile.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
-
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
